IGT Statement on House Re-Introduction of the MVP Act

Yesterday, Representative Brett Guthrie (R-KY), Chairman of the House Committee on Energy and Commerce, alongside Reps. Jake Auchincloss (D-MA), John Joyce, M.D. (R-PA), Scott Peters (D-CA), Mariannette Miller-Meeks (R-IA), and Don Davis (D-NC), reintroduced the Medicaid VBPs for Patients Act, or the MVP Act in the U.S. House. This follows Senate reintroduction of the MVP Act last year. The Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following statement: 

“We are grateful to Chairman Guthrie and his bipartisan colleagues for reintroducing this critical bill. The MVP Act is essential for aligning the rapid progress of gene therapy with the payment systems that ensure access to these groundbreaking, often life-saving treatments.Ensuring patients have timely access should be a shared, bipartisan priority, and as more therapies move toward approval, the need to modernize our reimbursement system becomes even more urgent. IGT is committed to working with Congress to move this legislation forward and deliver real solutions for patients and families facing genetic conditions.” 

Several patients, researchers, and other key stakeholders have expressed support for this legislation in recent years. For more information on the MVP act, click here.